Literature DB >> 24530974

Sexual function after vaginal and abdominal fistula repair.

Stefan Mohr1, Sonja Brandner2, Michael D Mueller2, Ekkehard F Dreher2, Annette Kuhn2.   

Abstract

OBJECTIVE: The purpose of this study was to compare clinical outcomes and sexual function between transvaginal and transabdominal repairs of vesicovaginal fistulae (VVF). STUDY
DESIGN: Participants (99 women with VVF at a tertiary referral center) were treated with urinary catheterization for 12 weeks and, if the procedure was unsuccessful, underwent repair using either the transvaginal (Latzko) or transabdominal technique. Objective clinical parameters were analyzed; subjective outcomes were recorded prospectively before surgery and at the 6-month follow-up examination with the use of the female sexual function index to evaluate sexual function and the visual analog scale to measure general disturbance by the fistula.
RESULTS: After bladder drainage for 12 weeks, 8 patients had spontaneous fistula closure. Demographic variables were similar in the transvaginal (n = 60) and transabdominal (n = 31) repair groups. The transvaginal procedure showed significantly shorter operation times, less blood loss, and shorter hospital stay. Continence rates 6 months after surgery were 82% (transvaginal) and 90% (transabdominal). Sexual function in the 64 sexually active patients was significantly improved, and overall disturbance by the fistula was reduced with both operative techniques. Neither surgical intervention was superior to the other regarding sexual function or visual analog scale.
CONCLUSION: Fistula repair improves sexual function and quality of life with no difference attributable to surgical route. Given this and that operating time, blood loss and length of stay are less with the transvaginal approach, the transvaginal approach is preferred in VVF repair if fistula and patient characteristics are suitable.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Latzko; sexual function; transabdominal repair; transvaginal repair; vesicovaginal fistula

Mesh:

Year:  2014        PMID: 24530974     DOI: 10.1016/j.ajog.2014.02.011

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Contemporary Outcomes of Surgery for Primary and Recurrent Genitourinary Fistulae in a Well-resourced Country.

Authors:  Nadir I Osman; Christopher J Hillary; Aziz Gulamhusein; Alison Downey; Richard D Inman; Christopher R Chapple
Journal:  Eur Urol Open Sci       Date:  2021-07-31

2.  Factors associated with the failure of obstetric fistula repair in Guinea: implications for practice.

Authors:  Alexandre Delamou; Therese Delvaux; Abdoul Habib Beavogui; Abdoulaye Toure; Delphin Kolié; Sidikiba Sidibé; Mandian Camara; Kindy Diallo; Thierno Hamidou Barry; Moustapha Diallo; Alain Leveque; Wei-Hong Zhang; Vincent De Brouwere
Journal:  Reprod Health       Date:  2016-11-08       Impact factor: 3.223

3.  The cost effectiveness of vaginal versus abdominal repair of vesicovaginal fistulae.

Authors:  Ross Warner; Alice Beardmore-Gray; Mahreen Pakzad; Rizwan Hamid; Jeremy Ockrim; Tamsin Greenwell
Journal:  Int Urogynecol J       Date:  2019-07-18       Impact factor: 2.894

Review 4.  Vesicovaginal fistula: Review and recent trends.

Authors:  Shanmugasundaram Rajaian; Murugavaithianathan Pragatheeswarane; Arabind Panda
Journal:  Indian J Urol       Date:  2019 Oct-Dec

5.  Factors associated with surgical repair success of female genital fistula in the Democratic Republic of Congo: Experiences of the Fistula Care Plus Project, 2017-2019.

Authors:  Michel Mpunga Mafu; Don Félicien Kyongolwa Banze; Brian Tena Tena Aussak; Delphin Kolié; Bienvenu Salim Camara; Dolores Nembunzu; Christine Notia Amisi; Justin Lussy Paluku; Vandana Tripathi; Alexandre Delamou
Journal:  Trop Med Int Health       Date:  2022-07-06       Impact factor: 3.918

6.  Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy.

Authors:  Alina Sturdza; Sandra Hofmann; Marlene Kranawetter; Stephan Polterauer; Christoph Grimm; Michael Krainer; Christian Kirisits; Richard Pötter; Alexander Reinthaller; Richard Schwameis
Journal:  Strahlenther Onkol       Date:  2017-07-18       Impact factor: 3.621

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.